Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
CC transcript
Larimar Therapeutics, Inc. (ZFGN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/18/2023 SC 13G JANUS HENDERSON GROUP PLC reports a 5.1% stake in Larimar Therapeutics, Inc.
08/14/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "2015 2020 2030 2035 2040 2045 2050 2055 2010 2025"
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results • Initiation cleared for 50 mg cohort in Phase 2 Friedreich's ataxia dose exploration trial following FDA review of unblinded 25 mg cohort Phase 2 data • Initiation cleared for open-label extension trial following FDA review of unblinded 25 mg cohort Phase 2 data • Top-line safety, pharmacokinetic, and frataxin data from the Phase 2 trial’s 50 mg cohort expected in 1H 2024 • Initiation of OLE trial with 25 mg daily dosing expected in Q1 2024; interim data expected in Q4 2024 • Cash, cash equivalents and marketable securities of $104.2 million as of June 30, 2023, provides projected cash runway into Q4 2024 Bala Cynwyd, PA,"
07/25/2023 8-K Quarterly results
07/24/2023 144 Form 144 - Report of proposed sale of securities:
07/17/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer"
06/01/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "2015 2020 2030 2035 2040 2045 2050 2055 2010 2025"
05/15/2023 8-K Quarterly results
Docs: "Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results • Safety data indicate that repeated subcutaneous injections of 25 mg CTI-1601 were generally well tolerated when administered daily for 14 days and then every-other-day thereafter until day 28 • Daily subcutaneous injections of 25 mg CTI-1601 for 14 days led to increases in frataxin levels from baseline compared to placebo in all evaluated tissues • Median placebo-adjusted increases from baseline of 3.5 pg/µg and 0.9 pg/µg in frataxin levels observed in skin and buccal cells, respectively, with 14 days of daily dosing of CTI-1601 • Larimar has submi...",
"16 17 18 19 15 20 21 22 23 24 25 26 27 28 2 3 4 5 1 6 7 8 9 10 11 12 13 14"
04/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/14/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/14/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/14/2023 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results",
"Larimar Therapeutics, Inc. Corporate Presentation"
02/14/2023 SC 13G PERCEPTIVE ADVISORS LLC reports a 6.6% stake in Larimar Therapeutics, Inc.
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer"
01/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "2015 2020 2030 2035 2040 2045 2050 2055 2010 2025"
11/22/2022 EFFECT Form EFFECT - Notice of Effectiveness:
11/14/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
11/10/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results - First cohort of Larimar’s Phase 2 dose exploration trial of CTI-1601 in Friedreich’s ataxia patients is ongoing and proceeding in line with the Company’s planned timeline - Larimar expects to provide an update on the Phase 2 trial in Q2 2023 and anticipates reporting top-line data from both cohorts in 2H 2023 - Cash of $124.7 million at September 30, 2022 provides projected cash runway into 2H 2024 Bala Cynwyd, PA,",
"2005 2010 2020 2025 2030 2035 2040 2045 2000 2015 TAT-MTS-FXN"
10/20/2022 8-K Quarterly results
09/16/2022 SC 13D/A Flynn James E reports a 42.4% stake in Larimar Therapeutics, Inc.
09/14/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement",
"Opinion of Troutman Pepper Hamilton Sanders LLP"
09/14/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
09/14/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich's Ataxia Patients",
"Larimar Therapeutics, Inc. Corporate Presentation"
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/11/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
05/12/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/12/2022 8-K Quarterly results
04/12/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy